A retrospective analysis of primary diagnosis, comorbidities, anticholinergic load, and other factors on treatment for noisy respiratory secretions at the end of life

Journal of Palliative Medicine

Volumn 14, Issue 11, 2011, Pages 1211-1216

  Sheehan, Caitlin ^a   Clark, Katherine ^b,c   Lam, Lawrence ^d   Chye, Richard ^e  

^a Cunningham Centre for Palliative Care   (Australia)

^b CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d UNIVERSITY OF NOTRE DAME   (Australia)

^e Sacred Heart Palliative Care Services   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPYRRONIUM BROMIDE; SCOPOLAMINE BROMIDE;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; BREATHING DISORDER; BRONCHUS SECRETION; COMORBIDITY; DRUG ACTIVITY; DRUG EFFICACY; DYING; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NOISE; NOISY RESPIRATORY SECRETION; PALLIATIVE THERAPY; RETROSPECTIVE STUDY; SALIVATION; SECRETION; TERMINAL CARE; TERMINALLY ILL PATIENT;

ADULT; AGED; AGED, 80 AND OVER; BODILY SECRETIONS; CHOLINERGIC ANTAGONISTS; COMORBIDITY; FEMALE; HOSPITAL UNITS; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEW SOUTH WALES; PALLIATIVE CARE; RESPIRATORY SOUNDS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TERMINALLY ILL;

EID: 80755125195     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0191     Document Type: Article

References (27)

1. Wildiers H, Menten J: Death rattle: Prevalence, prevention and treatment. J Pain Symptom Manage 2002;23: 310-317. (Pubitemid 34462943)
2. Hugel H, Ellershaw J, Gambles M: Respiratory tract secretions in the dying patient: A comparison between glycopyrronium and hyoscine hydrobromide. J Palliat Med 2006;9:279-284.
3. Bennett MI: Death rattle: An audit of hyoscine (Scopolamine) use and review of management. J Pain Symptom Manage 1996;12:229-233. (Pubitemid 26339153)
4. Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al: Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: A multicenter, prospective, observational study. J Pain Symptom Manage 2004;27:533-539. (Pubitemid 38686412)
5. Lichter I, Hunt E: The last 48 hours of life. J Pall Care 1990; 6:7-15.
6. Ellershaw JE, Sutcliffe JM, Saunders CM: Dehydration and the dying patient. J Pain Symptom Manage 1995;10:192-197.
7. Wee B, Hillier R: Interventions for noisy breathing in patients near to death. Cochrane Database Syst Rev 2008(1):CD005177.
8. Wee BL, Coleman PG, Hillier R, Holgate SH: The sound of death rattle I: Are relatives distressed by hearing this sound Palliat Med 2006;20:171-175.
9. Wee BL, Coleman PG, Hillier R, Holgate SH: The sound of death rattle II: How do relatives interpret the sound Palliat Med 2006;20:177-181.
10. Wee B, Coleman P, Hillier R, Holgate S: Death rattle: Its impact on staff and volunteers in palliative care. Palliat Med 2008;22:173-176. (Pubitemid 351597277)
11. Watts T, Jenkins K, Back I: Problem and management of noisy rattling breathing in dying patients. Int J Palliat Nurs 1997;3:245-252.
12. Clark K, Butler M: Noisy respiratory secretions at the end of life. Curr Opin Supp Palliat Care 2009;3:120-124.
13. Wildiers H, Dhaenekint C, Demeulenaere P, Clement PMJ, Desmet M, Van Nuffelen R, et al: Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage 2009;38:124-133.
14. Morita T, Tsunoda J, Inoue S, Chihara S: Risk factors for death rattle in terminally ill cancer patients: A prospective exploratory study. Palliat Med 2000;14:19-23 (Pubitemid 30095222)
15. Kass RM Ellershaw J: Respiratory tract secretions in the dying patient: A retrospective study. J Pain Symptom Manage 2003 26 897-902.
16. Agar M, Currow D, Plummer J, Seidel R, Carnahan R, Abernethy AP: Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med 2009;23:257-265.
17. Bachrach SJ, Walter RS, Trzcinski K: Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. Clin Pediatr 1998;37:485-490. (Pubitemid 28378245)
18. Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M Treatment of sialorrhea with glycopyrrolate: A double-blind dose-ranging study.Arch PediatrAdolescMed 2000 154 1214-1218.
19. Eagar K, Green J, Gordon R: An Australian casemix classification for palliative care: Technical development and results. Palliat Med 2004;18:217-226. (Pubitemid 38771661)
20. Carnahan RM, Lund BC Perry PJ, Pollock BG, Culp KR: The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharma 2006;46:1481-1486. (Pubitemid 44704208)
21. Clark K, Lam L, Agar M, Chye R, Currow D: The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: A retrospective analysis. Palliat Med 2010;24: 410-418.
22. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE: The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168:508-513. (Pubitemid 351547214)
23. Bhanji NH, Chouinard G, Kolivakis T, Margolese HC: Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharma 2006; 13:e69-e74. (Pubitemid 46165600)
24. Howland RH: Potential adverse effects of discontinuing psychotropic drugs: Part 1: adrenergic, cholinergic, and histamine drugs. J Psychosoc Nurs Mental Health Serv 2010;48:11-14.
25. Majocha R, Baldessarini RJ: Tolerance to an anticholinergic agent is paralleled by increased binding to muscarinic receptors in rat brain and increased behavioral response to a centrally active cholinomimetic. Life Sciences 1984;35:2247-2255. (Pubitemid 15202087)
26. Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al: Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignancies. J Pain Symptom Manage 2006;31:130-139. (Pubitemid 43243666)
27. Morita T, Hyodo I, Yoshimi T, Ikenaga M, Tamura Y, Yoshizawa A, et al: Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Ann Oncol 2005;16:640-647. (Pubitemid 40613332)